Contrasting Tandem Diabetes Care (NASDAQ:TNDM) & IceCure Medical (NASDAQ:ICCM)

Tandem Diabetes Care (NASDAQ:TNDM) and IceCure Medical (NASDAQ:ICCM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Risk & Volatility

Tandem Diabetes Care has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, IceCure Medical has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500.

Valuation and Earnings

This table compares Tandem Diabetes Care and IceCure Medical’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tandem Diabetes Care	$747.72 million	2.63	-$222.61 million	($3.44)	-8.85
IceCure Medical	$3.23 million	17.09	-$14.65 million	($0.33)	-3.67

IceCure Medical has lower revenue, but higher earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for Tandem Diabetes Care and IceCure Medical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tandem Diabetes Care	1	6	5	0	2.33
IceCure Medical	0	0	2	0	3.00

Tandem Diabetes Care currently has a consensus price target of $37.00, suggesting a potential upside of 21.59%. IceCure Medical has a consensus price target of $2.95, suggesting a potential upside of 143.80%. Given IceCure Medical’s stronger consensus rating and higher possible upside, analysts plainly believe IceCure Medical is more favorable than Tandem Diabetes Care.

Insider and Institutional Ownership

0.6% of IceCure Medical shares are held by institutional investors. 2.5% of Tandem Diabetes Care shares are held by company insiders. Comparatively, 2.4% of IceCure Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Tandem Diabetes Care and IceCure Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tandem Diabetes Care	-29.77%	-31.48%	-10.75%
IceCure Medical	-453.76%	-86.96%	-68.63%

About Tandem Diabetes Care

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.